Consolidation or maintenance therapy for advanced ovarian cancer

doi:10.3760/cma.j.issn.1673-422X.2014.01.019

Abstract

Abstract: Consolidation therapy or maintenance therapy for complete response to conventional treatment can delay recurrence of ovarian cancer. Consolidation or maintenance therapy programs include chemotherapy, radiotherapy and biological treatment. Clinical trials confirm that these treatment agents have their advantages and disadvantages, and the effects are quite different. Now scientists are still exploring new agents, for finding the best pathway to delay or even prevent recurrence.

Key words: Ovarian neoplasms, Treatment outcome, Consolidation therapy

Xia Ting, Yu Aijun. Consolidation or maintenance therapy for advanced ovarian cancer[J]. Journal of International Oncology, 2014, 41(1): 60-62.

References

［1］ Ozols RF. Maintenance therapy in advanced ovarian cancer: progressionfree survival and clinical benefit［J］. J Clin Oncol, 2003, 21(13):24512453. ［2］ Markman M, Liu PY, Wilczynski S, et al. Phase Ⅲ randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxelbased chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group Trial［J］. J Clin Oncol, 2003, 21(13):24602465. ［3］ Markman M, Liu PY, Moon J, et al. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinumpaclitaxel: followup of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial［J］. Gynecol Oncol, 2009, 114(2):195198. ［4］ Pecorelli S, Favalli G, Gadducci A, et al. Phase Ⅲ trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinumbased chemotherapy: final results of the after6 protocol 1［J］. J Clin Oncol, 2009, 27(28):46424648. ［5］ De Placido S, Scambia G, Di Vagno G, et al. Topotecan compared with no therapy after response to surgery and carboplatin/paelitaxel in patients with ovarian cancer: multicenter italian trials in ovarian cancer (M1TO1) randomized study［J］. J Clin Oncol, 2004, 22(13):26352642. ［6］ Kim JH, Lee JM, Ryu KS, et al. Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer［J］. J Surg Oncol, 2010, 101(2):149155. ［7］ Sorbe B. Consolidation treatment of advanced ovarian carcinoma with radiotherapy after induction chemotherapy［J］. Int J Gynecol Cancer, 2003, 13 Suppl 2:192195. ［8］ Berek J, Taylor P, McGuire W, et al. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cance［J］. J Clin Oncol, 2009, 27(3):418425. ［9］ Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primarytreatment of ovarian cancer［J］. N Engl J Med, 2011, 365(26):24732483. ［10］ Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer［J］. N Engl J Med, 2011, 365(26):24842496.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Wang Kun, Zhou Zhongxin, Zang Qiwei. Predictive value of serum TGF-β1 and VEGF levels in patients with non-small cell lung cancer after single-port thoracoscopic radical resection [J]. Journal of International Oncology, 2024, 51(4): 198-203.
[3]	Yan Aiting, Wang Cuizhu, Liu Chungui, Lu Xiaomin. Clinical efficacy and safety of camrelizumab and sintilimab in the treatment of advanced non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 137-142.
[4]	Gong Yan, Chen Honglei. Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer [J]. Journal of International Oncology, 2024, 51(3): 186-190.
[5]	Jiang Xi, Wu Yongcun, Liang Yan, Chu Li, Duan Yingxin, Wang Lijun, Huo Junjie. Impact of pembrolizumab combined with chemotherapy on angiogenesis and circulating endothelial cells in patients with advanced non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(2): 89-94.
[6]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[7]	An Rong, Liu Meihua, Wang Peichen, Wang Xiaohui. Research progress of Nrf2 in ovarian cancer [J]. Journal of International Oncology, 2023, 50(8): 493-497.
[8]	Li Chenxi, Zhao Hongwei. Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery [J]. Journal of International Oncology, 2023, 50(6): 342-347.
[9]	Yang Lirong, Wang Yufeng. Construction of machine learning models for predicting the risk of postoperative distant metastasis recurrence in serous ovarian cancer [J]. Journal of International Oncology, 2023, 50(4): 220-226.
[10]	Zhou Ting, Xu Shaohua, Mei Lin. Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer [J]. Journal of International Oncology, 2023, 50(3): 144-149.
[11]	Cao Mengqing, Xu Zhiyong, Shi Yuting, Wang Kai. Role of tertiary lymphoid structures in tumor immune microenvironment regulation and anti-tumor therapy [J]. Journal of International Oncology, 2023, 50(3): 169-173.
[12]	Wang Bing, Wang Aifu, Liu Wenshu, Fan Jiaojiao, Tian Weicheng, Wang Weili, Liu Boyu. The efficacy and safety of recombinant human thrombopoietin in the treatment of thrombocytopenia caused by tumor radiotherapy [J]. Journal of International Oncology, 2023, 50(11): 661-667.
[13]	Liu Song, Yu Guangji, Wang Qingdong. Efficacy and influencing factors of DEBIRI-TACE combined with regorafenib in the third-line or above treatment of colorectal cancer liver metastases [J]. Journal of International Oncology, 2022, 49(7): 400-407.
[14]	Cai Gangxiang, Li Jing, Xu Bin. Advances in neoadjuvant immunotherapy for lung cancer [J]. Journal of International Oncology, 2022, 49(6): 366-370.
[15]	Ding Xinjing, Ding Jianghua. Research progress on the correlation between dermatological immune-related adverse events and clinical outcome of PD-1/PD-L1 inhibitors [J]. Journal of International Oncology, 2022, 49(4): 225-228.